Phase 2 RCT in 80 people with suppressed HIV-1: at week 26, 1.9% (1/53) on twice-yearly lenacapavir, teropavimab and zinlirvimab vs 0/27 continuing oral ART had HIV-1 RNA of 50 copies/mL or higher; no serious adverse events with the combination.
RCTn = 80
Ogbuagu et al. Efficacy and safety of lenacapavir, teropavimab, and zinlirvimab: week-26 primary outcome results from a multicentre, open-label, randomised, active-controlled, phase 2 study